Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients

Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients

Aim: Kukoamine B, a small molecule compound, is being developed for the treatment of sepsis in a Phase II clinical trial. The objective of this study was to optimize dosing selection for a Phase IIb clinical trial using an exposure-response model.Methods: Data of 34 sepsis patients from a Phase IIa...

Full description

Bibliographic Details
Main Authors: Huanhuan Wang, Xiaoyun Hu, Teng Wang, Cheng Cui, Ji Jiang, Kai Dong, Shuai Chen, Chunyan Jin, Qian Zhao, Bin Du, Pei Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Pharmacology
Subjects:
SOFA score
sepsis
exposure-response modeling
model validation
simulation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.645130/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.645130/full

Similar Items